glp-1 for nash fatty liver Multiple target tissue effects of analogues on non-alcoholic disease (NAFLD) and non-alcoholic steatohepatitis (NASH) 🔬 Big news anyone – GLP-1 and Nonalcoholic Steatohepatitis |

Another critical aspect is the variability in supplement formulations

Semaglutide is not indicated for type 1 diabetes

health panels move tremendously frustrating: expert Timothy Caulfield, a health law expert, said the FDA advisory panels decision is tremendously frustrating. I certainly hope that it doesnt influence what Health Canada does

It focuses on the SURPASS and SURMOUNT clinical trial programs, presently the best evaluations of Tirzepatide's clinical efficacy

Supplementation of mice with FLAVOmega (a mixture of flavonoids and docosahexaenoic acid) ameliorated the pathological phenotype in dystrophic mice, as reflected by decreasing ROS production, suppressed inflammation and fibrosis, an oxidative metabolic switch of myofibrosis as well as increased mitochondrial activity, fatigue resistance, and vascularization